News

Despite the recent advancements in the treatment of polymyalgia rheumatica, a need for more research focused on finding non-steroidal treatment options remains.

Although women with gout reported more severe symptoms and significantly worse illness perception and quality of life, they were given less information on ways to self-manage their condition.

Results revealed 92.45% of patients with fibromyalgia were simultaneously diagnosed with at least 1 type of psychiatric disorder, although most were diagnosed with 2 or more.

An analysis of data from patients presented to a pair of clinics in Greece over a 5-year period provides insight into potential differences in disease course, management, and presentation of psoriatic arthritis based on age at diagnosis.

Results from the SELECT-PsA trials indicate patients with active PsA and axial involvement demonstrated greater clinical improvement with upadacitinib 15 mg versus placebo.

No significant changes in the rate of flares during the 6-month period pre- or post-vaccination were observed in patients with either rheumatoid arthritis or psoriatic arthritis.

No significant differences in the risk of myocardial infarction and other cardiovascular events were observed between patients with gout who received colchicine and those who did not.

Both drugs were well tolerated and without any serious adverse events.

Patients with cirrhosis had higher mortality rates, tophi, and gout flare.

An analysis of eGFR changes based on methotrexate use in the MIRROR trial offers new insight into the effects of pegloticase on renal function.

Patients with psoriatic arthritis had increased risks of non-melanoma skin cancer, lymphoma, and thyroid cancer compared with the general population.

The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.

The meta-analysis observed an enhanced plasma uric acid concentration in patients with periodontitis when compared with controls.

At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.

At week 24, serum IGF-1 levels increased and body weight was reduced by an average of 6.5% from baseline.

In a multivariate logistic regression analysis, the HAQ score was significantly associated with both anxiety and depression, indicating worse functional status and higher disease activity.

The collaboration, titled the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), is the first public-private partnership designed to advance lupus discoveries and highlight patient perspective in drug development.

A cross-sectional, case-controlled cohort study evaluated the cardiorespiratory and neuromuscular fitness of Finnish patients with JIA and healthy controls.

Treatment with secukinumab was safe and effective for patients with ankylosing spondylitis and psoriatic arthritis, with significant reductions in disease activity scores observed through 52 weeks.

The guidelines were created using a panel of rheumatologists, orthopedic surgeons, and patients.

New meta-analysis show patient demographics—as well as their pre-existing comorbidities and COVID-19 vaccination status—may significantly define their risk of long-term conditions.

Compared with other bDMARDs, patients with rheumatoid arthritis treated with tofacitinib had a 4-fold reduced incidence of interstitial lung disease.

A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

The systematic review summarized the impact of biologics targeting the IL-23/Th17 axis.

An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.

Often overlooked and underfunded, as well as being underpaid compared to internal medicine, it is difficult to convince prospective medical students, many of whom already have substantial debt, to choose a career in pediatric rheumatology.

The phase 3 DISCOVER-1 and DISCOVER-2 studies were used to evaluate dactylitis resolution in guselkumab-treated patients with psoriatic arthritis through 1 year.